Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia - Related Studies

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

This study has been terminated.

Study NCT00113802. Last updated on February 4, 2008. Information provided by Immunomedics, Inc.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Waldenstrom Macroglobulinemia

2	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Plasma Cell
		Paraproteinemias
		Vascular Diseases

3	Additional drug interventions recognized in this trial
		Antibodies

4	More general drug interventions related to this trial
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

5	Sponsors listed in this trial
		Immunomedics, Inc.